Press Releases

January 9, 2023

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Press Releases

January 9, 2023

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Press Releases

January 9, 2023

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Press Releases

January 9, 2023

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Press Releases

January 9, 2023

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Press Releases

January 9, 2023

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Press Releases

December 23, 2022

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Press Releases

December 23, 2022

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Press Releases

December 23, 2022

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Press Releases

December 23, 2022

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Press Releases

December 23, 2022

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Press Releases

December 23, 2022

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Press Releases

December 5, 2022

Acticor Biotech receives European Medicines Agency (EMA) endorsement on key parameters of ACTISAVE, its pivotal Phase II/III study for registration in Stroke

Press Releases

December 5, 2022

Acticor Biotech receives European Medicines Agency (EMA) endorsement on key parameters of ACTISAVE, its pivotal Phase II/III study for registration in Stroke

Press Releases

December 5, 2022

Acticor Biotech receives European Medicines Agency (EMA) endorsement on key parameters of ACTISAVE, its pivotal Phase II/III study for registration in Stroke

Press Releases

December 5, 2022

Acticor Biotech receives European Medicines Agency (EMA) endorsement on key parameters of ACTISAVE, its pivotal Phase II/III study for registration in Stroke

Press Releases

December 5, 2022

Acticor Biotech receives European Medicines Agency (EMA) endorsement on key parameters of ACTISAVE, its pivotal Phase II/III study for registration in Stroke

Press Releases

December 5, 2022

Acticor Biotech receives European Medicines Agency (EMA) endorsement on key parameters of ACTISAVE, its pivotal Phase II/III study for registration in Stroke

Press Releases

December 1, 2022

Acticor Biotech announces its financial agenda for the 1st half of 2023

Press Releases

December 1, 2022

Acticor Biotech announces its financial agenda for the 1st half of 2023

Press Releases

December 1, 2022

Acticor Biotech announces its financial agenda for the 1st half of 2023

Press Releases

December 1, 2022

Acticor Biotech announces its financial agenda for the 1st half of 2023

Press Releases

December 1, 2022

Acticor Biotech announces its financial agenda for the 1st half of 2023

Press Releases

December 1, 2022

Acticor Biotech announces its financial agenda for the 1st half of 2023

Press Releases

November 22, 2022

World’s first clinical trial to test new drug glenzocimab for heart attacks

Press Releases

November 22, 2022

World’s first clinical trial to test new drug glenzocimab for heart attacks

Press Releases

November 22, 2022

World’s first clinical trial to test new drug glenzocimab for heart attacks

Press Releases

November 22, 2022

World’s first clinical trial to test new drug glenzocimab for heart attacks

Press Releases

November 22, 2022

World’s first clinical trial to test new drug glenzocimab for heart attacks

Press Releases

November 22, 2022

World’s first clinical trial to test new drug glenzocimab for heart attacks

Press Releases

October 27, 2022

Acticor Biotech announces its 2022 half-year financial results and update on its clinical progress

Press Releases

October 27, 2022

Acticor Biotech announces its 2022 half-year financial results and update on its clinical progress

Press Releases

October 27, 2022

Acticor Biotech announces its 2022 half-year financial results and update on its clinical progress

Press Releases

October 27, 2022

Acticor Biotech announces its 2022 half-year financial results and update on its clinical progress

Press Releases

October 27, 2022

Acticor Biotech announces its 2022 half-year financial results and update on its clinical progress

Press Releases

October 27, 2022

Acticor Biotech announces its 2022 half-year financial results and update on its clinical progress

Press Releases

October 18, 2022

Acticor Biotech strenghtens its financial structure

Press Releases

October 18, 2022

Acticor Biotech strenghtens its financial structure

Press Releases

October 18, 2022

Acticor Biotech strenghtens its financial structure

Press Releases

October 18, 2022

Acticor Biotech strenghtens its financial structure

Press Releases

October 18, 2022

Acticor Biotech strenghtens its financial structure

Press Releases

October 18, 2022

Acticor Biotech strenghtens its financial structure

Press Releases

September 26, 2022

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Press Releases

September 26, 2022

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Press Releases

September 26, 2022

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Press Releases

September 26, 2022

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Press Releases

September 26, 2022

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Press Releases

September 26, 2022

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Press Releases

September 23, 2022

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Press Releases

September 23, 2022

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Press Releases

September 23, 2022

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Press Releases

September 23, 2022

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Press Releases

September 23, 2022

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Press Releases

September 23, 2022

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Press Releases

July 21, 2022

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Press Releases

July 21, 2022

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Press Releases

July 21, 2022

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Press Releases

July 21, 2022

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Press Releases

July 21, 2022

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Press Releases

July 21, 2022

Press Releases

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Acticor Biotech receives European Medicines Agency (EMA) endorsement on key parameters of ACTISAVE, its pivotal Phase II/III study for registration in Stroke

Acticor Biotech receives European Medicines Agency (EMA) endorsement on key parameters of ACTISAVE, its pivotal Phase II/III study for registration in Stroke

Acticor Biotech receives European Medicines Agency (EMA) endorsement on key parameters of ACTISAVE, its pivotal Phase II/III study for registration in Stroke

Acticor Biotech receives European Medicines Agency (EMA) endorsement on key parameters of ACTISAVE, its pivotal Phase II/III study for registration in Stroke

Acticor Biotech receives European Medicines Agency (EMA) endorsement on key parameters of ACTISAVE, its pivotal Phase II/III study for registration in Stroke

Acticor Biotech receives European Medicines Agency (EMA) endorsement on key parameters of ACTISAVE, its pivotal Phase II/III study for registration in Stroke

Acticor Biotech announces its financial agenda for the 1st half of 2023

Acticor Biotech announces its financial agenda for the 1st half of 2023

Acticor Biotech announces its financial agenda for the 1st half of 2023

Acticor Biotech announces its financial agenda for the 1st half of 2023

Acticor Biotech announces its financial agenda for the 1st half of 2023

Acticor Biotech announces its financial agenda for the 1st half of 2023

World’s first clinical trial to test new drug glenzocimab for heart attacks

World’s first clinical trial to test new drug glenzocimab for heart attacks

World’s first clinical trial to test new drug glenzocimab for heart attacks

World’s first clinical trial to test new drug glenzocimab for heart attacks

World’s first clinical trial to test new drug glenzocimab for heart attacks

World’s first clinical trial to test new drug glenzocimab for heart attacks

Acticor Biotech announces its 2022 half-year financial results and update on its clinical progress

Acticor Biotech announces its 2022 half-year financial results and update on its clinical progress

Acticor Biotech announces its 2022 half-year financial results and update on its clinical progress

Acticor Biotech announces its 2022 half-year financial results and update on its clinical progress

Acticor Biotech announces its 2022 half-year financial results and update on its clinical progress

Acticor Biotech announces its 2022 half-year financial results and update on its clinical progress

Acticor Biotech strenghtens its financial structure

Acticor Biotech strenghtens its financial structure

Acticor Biotech strenghtens its financial structure

Acticor Biotech strenghtens its financial structure

Acticor Biotech strenghtens its financial structure

Acticor Biotech strenghtens its financial structure

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Acticor Biotech postpones release of its 2022 Half-Year Financial Results

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Subscribe to email alert

Navigation

Contact Us